Niveles séricos de 25-hidroxivitamina D y su relación con síndrome metabólico en una población de hombres jóvenes no diabéticos / Serum levels of 25-hydroxy vitamin D and their relationship to metabolic syndrome in a population of young nondiabetic men

Resumen Introducción: los niveles no suficientes de vitamina D (VD) se han asociado a varias patologías no osteomusculares; sin embargo, es motivo de controversia si éstos se asocian a mayor prevalencia de síndrome metabólico (SM). Objetivo: determinar y comparar la frecuencia de insuficiencia y deficiencia de 25-hidroxivitamina D (25(OH)D) entre hombres jóvenes obesos no diabéticos y controles con peso normal, y su correlación con el estado de SM. Material y métodos: estudio de corte transversal, que incluyó 62 individuos con peso normal y 47 en obesidad, se determinaron los niveles séricos de 25(OH)D y se midieron parámetros antropométricos y bioquímicos para establecer criterios de SM. Resultados: de los 47 sujetos con obesidad, 25 tenían SM, mientas que ninguno de los sujetos de peso normal cumplía con dichos criterios. No se encontraron diferencias estadísticamente significativas en cuanto a la presencia de síndrome en correlación con los niveles de vitamina D (p=0.94). La media de los niveles séricos de 25(OH)D para la población total fue 30.6±8.3 ng/ mL; en sujetos normopeso 30.8±8.5 ng/mL y entre los obesos con SM fue 30.1±9.2 ng/mL y sin SM de 30.6±7.5 ng/mL. Por otro lado no hubo una correlación significativa entre los parámetros individuales de síndrome metabólico y los niveles séricos de VD, tanto de manera global, como en el análisis por subgrupos. Conclusión: no hubo una correlación significativa entre los niveles séricos de 25(OH)D con el estado de SM, tampoco se identificó ningún tipo de correlación significativa entre éstos y los parámetros antropométricos y bioquímicos estudiados.(Acta Med Colomb 2020; 45. DOI:doi.org/10.36104/amc.2020.1323).

Abstract Introduction: insufficient levels of vitamin D (VD) have been associated with several non-musculoskeletal diseases. However, whether they are associated with a greater prevalence of metabolic syndrome (MS) is a matter of controversy. Objective: to determine and compare the frequency of 25-hydroxy vitamin D (25(OH)D) insufficiency and deficiency in young, obese nondiabetic men and normal weight controls, and its correlation with metabolic syndrome. Material and methods: a cross-sectional study which included 62 normal weight and 47 obese individuals. Serum levels of 25(OH)D were ascertained and anthropometric and biochemical parameters were measured to establish MS criteria. Results: of the 47 obese subjects, 25 had MS, while none of the normal weight subjects met the criteria. There were no statistically significant differences in the presence of the syndrome related to the vitamin D levels (p=0.94). The mean serum 25(OH)D level for the total population was 30.6±8.3 ng/mL; in normal weight subjects it was 30.8±8.5 ng/mL, in obese subjects with MS it was 30.1±9.2 ng/mL, and in obese subjects without MS it was 30.6±7.5 ng/mL. Furthermore, there was no significant correlation between the individual MS parameters and serum VD, either globally or on subgroup analysis. Conclusion: there was no significant correlation between serum 25(OH)D levels and MS, nor was any significant correlation found between these and the anthropometric and biochemical parameters studied.(Acta Med Colomb 2020; 45. DOI:https://doi.org/10.36104/amc.2020.1323).

Serum Galanin Levels in Young Healthy Lean and Obese Non-Diabetic Men during an Oral Glucose Tolerance Test.

Galanin (GAL) is a neuropeptide involved in the homeostasis of energy metabolism. The objective of this study was to investigate the serum levels of GAL during an oral glucose tolerance test (OGTT) in lean and obese young men. This cross-sectional study included 30 obese non-diabetic young men (median 22 years; mean BMI 37 kg/m(2)) and 30 healthy lean men (median 23 years; mean BMI 22 kg/m(2)). Serum GAL was determined during OGTT. The results of this study include that serum GAL levels showed a reduction during OGTT compared with basal levels in the lean subjects group. Conversely, serum GAL levels increased significantly during OGTT in obese subjects. Serum GAL levels were also higher in obese non-diabetic men compared with lean subjects during fasting and in every period of the OGTT (p < 0.001). Serum GAL levels were positively correlated with BMI, total fat, visceral fat, HOMA-IR, total cholesterol, triglycerides and Leptin. A multiple regression analysis revealed that serum insulin levels at 30, 60 and 120 minutes during the OGTT is the most predictive variable for serum GAL levels (p < 0.001). In conclusion, serum GAL levels are significantly higher in the obese group compared with lean subjects during an OGTT.

Niveles séricos del factor neurotrófico derivado del cerebro durante la gestación normal y la preeclampsia / Serum Levels of Brain Derived Neurotrophic Factor during Normal Pregnancy and Preeclampsia

Introducción. La preeclampsia (PE) es una de las principales causas de mortalidad materna y perinatal en el mundo, aparece en la segunda mitad de la gestación y actualmente no hay marcadores que la detecten en forma temprana. Dadas las propiedades angiogénicas del factor neurotrófico derivado del cerebro (BDNF) y la disfunción endotelial de los vasos sanguíneos presente en la PE, se ha propuesto una posible asociación entre el BDNF y PE. Objetivo. Determinar si existe asociación entre niveles séricos de BDNF durante el embarazo y la preeclampsia. Materiales y métodos. Estudio de cohorte prospectivo longitudinal. Se seleccionaron 13 pacientes quienes desarrollaron PE y 31 gestantes de curso normal. Se midieron variables antropométricas y niveles de BDNF, glicemia, insulina y perfil lipídico en la gestación temprana, media y tardía. Se practicó un modelo de regresión logística para verificar si los niveles de BDNF, en conjunto con otras variables, pueden explicar el desarrollo de PE. Resultados. Los niveles de BDNF no variaron significativamente entre el grupo de gestantes que desarrollaron preeclampsia y las que no: en gestación temprana 25.3 y 23.3ng/ml, en gestación media 28 y 24.7ng/ml y en gestación tardía 25.4 y 27.4ng/ml, respectivamente. Se hallaron diferencias entre los dos grupos en el peso, la insulina y la evaluación del modelo homeostático (HOMA). Se encontró asociación entre niveles de BDNF y peso e IMC y glucemia en las gestantes que no desarrollaron PE. Se practicó un modelo de regresión logística en el que la PE se explicó mejor con variables como IMC, PAS y HOMA, pero no con BDNF. Conclusiones. El BDNF puede participar en la regulación del peso corporal y el metabolismo de la glucosa en mujeres gestantes, pero el nivel de BDNF, solo o en conjunto con otras variables, no puede explicar la preeclampsia.

Introduction. Preeclampsia (PE) is one of the major causes of maternal and perinatal mortality in the world. PE appears during the second half of pregnancy and there are currently no markers for its early detection. Given the angiogenic properties of brain derived neurotrophic factor (BDNF) and the endothelial dysfunction of blood vessels that occurs during PE, an association between BDNF and PE has been proposed. Objective. To determine if there is an association between BDNF serum levels and PE during pregnancy. Materials and Methods. Prospective longitudinal cohort study. 13 patients who developed PE and 31 patients with normally coursing pregnancies were selected. Anthropometric variables, BDNF serum levels, glycemia, insulin and lipid profile in early, mid-term and late pregnancies were measured. Results. No significant differences were observed in BDNF levels between women who developed PE and those who did not; in early pregnancy the levels were 25.3 and 23.3 ng/ml, for mid-term pregnancy 28 and 24.7 ng/ml and for late pregnancy 25.4 and 27.4 ng/ml for PE and normal pregnancy, respectively. An association between BDNF and weight and BMI and serum glucose was found in women who did not develop PE. A logistic regression model was carried out where PE was better explained through variables such as BMI, SBP and homoeostasis model assessment (HOMA), however BDNF was not taken into account here. Conclusions. BDNF might have a role in regulating body weight and glucose metabolism in pregnant women but there is no evidence to suggest that BDNF alone or in combination with other variables can account for PE.